Cargando…
The Anticancer Effects of FDI-6, a FOXM1 Inhibitor, on Triple Negative Breast Cancer
Triple-negative breast cancer (TNBC) presents an important clinical challenge, as it does not respond to endocrine therapies or other available targeting agents. FOXM1, an oncogenic transcriptional factor, has reported to be upregulated and associated with poor clinical outcomes in TNBC patients. In...
Autores principales: | Ulhaka, Karan, Kanokwiroon, Kanyanatt, Khongkow, Mattaka, Bissanum, Rassanee, Khunpitak, Thanaporn, Khongkow, Pasarat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269391/ https://www.ncbi.nlm.nih.gov/pubmed/34206484 http://dx.doi.org/10.3390/ijms22136685 |
Ejemplares similares
-
Integrated bioinformatic analysis of potential biomarkers of poor prognosis in triple-negative breast cancer
por: Bissanum, Rassanee, et al.
Publicado: (2022) -
Molecular Classification Models for Triple Negative Breast Cancer Subtype Using Machine Learning
por: Bissanum, Rassanee, et al.
Publicado: (2021) -
Interruptin C, a Radioprotective Agent, Derived from Cyclosorus terminans Protect Normal Breast MCF-10A and Human Keratinocyte HaCaT Cells against Radiation-Induced Damage
por: Chumsuwan, Nipha, et al.
Publicado: (2022) -
Ethosomes of Phenylethyl Resorcinol as Vesicular Delivery System for Skin Lightening Applications
por: Limsuwan, Tunyaluk, et al.
Publicado: (2017) -
Vesicular carriers containing phenylethyl resorcinol for topical delivery system; liposomes, transfersomes and invasomes
por: Amnuaikit, Thanaporn, et al.
Publicado: (2018)